한글목차

애디슨병 세계 시장은 2024년에 4억 3,312만 달러로 평가되었고, 2030년까지 예측 기간 동안 6.88%의 연평균 복합 성장률(CAGR)을 보이고, 6억 4,656만 달러에 달할 것으로 예측됩니다.

애디슨병 세계 시장은 인지도 향상, 진단 도구의 발전, 치료 접근성 향상으로 인해 꾸준히 성장하고 있습니다. 애디슨병은 부신 기능 부전으로 인한 희귀 내분비 질환으로 호르몬 대체 요법을 통한 평생 관리가 필요한 질환입니다. 애디슨병의 주요 원인인 자가면역질환의 유병률 증가는 효과적인 치료 솔루션에 대한 수요 증가에 기여하고 있습니다. 재생의료와 유전자 치료 등 혁신적인 치료법에 초점을 맞춘 연구 개발이 시장 환경을 더욱 형성하고 있습니다. 내분비 질환 연구에 대한 투자 증가와 새로운 제제 개발에 대한 제약사들의 노력은 시장 확대를 뒷받침하고 있습니다. 의료 인프라의 개선과 각국의 개선된 상환 정책은 진단과 치료에 대한 더 나은 접근성을 보장하고 시장 성장을 더욱 촉진하고 있습니다.

주요 시장 성장 촉진요인

인지도 향상 및 조기 진단

주요 시장 과제

높은 치료비

주요 시장 동향

연구개발에 대한 노력

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 애디슨병 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(원발성 부신 기능 부전, 2차성 부신 기능 부전, 3차성 부신 기능 부전)
  • 약제 클래스별(경구 코르티코스테로이드, 코르티코스테로이드 주사, 나트륨 섭취)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 유형별
  • 약제 클래스별
  • 유통 채널별
  • 지역별

제5장 아시아태평양의 애디슨병 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 약제 클래스별
  • 유통 채널별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 애디슨병 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 애디슨병 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
  • 유형
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 애디슨병 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 애디슨병 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 애디슨병 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Teva Pharmaceuticals
• Ralington Pharma
• Aspen Pharma
• Pfizer Inc
• Merck KGaA
• Anant Pharmaceuticals
• Symbiotech
• Curia
• AuroPharma
• Parchem Fine & Specialty Chemicals

제15장 전략적 제안

제16장 회사 소개 및 면책조항

영문목차

Global Addison's Disease Market was valued at USD 433.12 Million in 2024 and is expected to reach USD 646.56 Million in the forecast period with a CAGR of 6.88% through 2030. The Global Addison's Disease Market is experiencing steady growth due to increased awareness, advancements in diagnostic tools, and improved access to treatment. Addison's Disease, a rare endocrine disorder caused by adrenal insufficiency, requires lifelong management with hormone replacement therapy. The rising prevalence of autoimmune disorders, which are a primary cause of Addison's Disease, has contributed to the growing demand for effective treatment solutions. Research and development efforts focused on innovative therapies, including regenerative medicine and gene therapy, are further shaping the market landscape. Increasing investments in endocrine disorder research, coupled with pharmaceutical companies' efforts to develop novel drug formulations, are supporting market expansion. Enhanced healthcare infrastructure and improved reimbursement policies in various countries are ensuring better access to diagnosis and treatment, further fueling market growth.

Key Market Drivers

Increasing Awareness and Early Diagnosis

Increasing awareness and early diagnosis have become pivotal in driving the growth of the global Addison's Disease market. This rare endocrine disorder, characterized by insufficient production of cortisol and aldosterone, often manifests with nonspecific symptoms such as fatigue, weakness, weight loss, and low blood pressure, making accurate diagnosis challenging. However, concerted efforts by healthcare professionals, advocacy groups, and awareness campaigns have significantly enhanced recognition of Addison's Disease among both medical practitioners and the general population. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Addison's disease affects about 100 to 140 of every million people in developed countries.

The heightened awareness has led to a greater index of suspicion among healthcare providers when evaluating patients with relevant symptoms. Consequently, individuals suspected of having adrenal insufficiency are more promptly referred for diagnostic testing, facilitating earlier diagnosis. Early detection is crucial, as it allows for the timely initiation of hormone replacement therapy, preventing potentially life-threatening adrenal crises and improving overall patient outcomes. Notably, the NIDDK reports that women are more likely than men to develop Addison's disease, with the condition occurring most often in people between the ages of 30 and 50.

Key Market Challenges

High Treatment Costs

High treatment costs are a significant barrier to progress in the global Addison's Disease market. Addison's Disease, a rare endocrine disorder characterized by insufficient cortisol and aldosterone production, requires lifelong hormone replacement therapy. While this therapy is essential for patients, the financial burden it places on individuals and healthcare systems can be overwhelming. The primary component of Addison's Disease treatment is hormone replacement therapy, primarily involving corticosteroids. These medications are effective in managing the symptoms and improving the quality of life for patients. However, the cost of these medications can be prohibitive, making access to treatment a challenge for many individuals.

The high cost of Addison's Disease treatment stems from several factors. Firstly, corticosteroid medications are not inexpensive to produce, and their pricing can vary significantly between different formulations and brands. This variation in pricing can lead to disparities in care, with some patients unable to afford the specific medication that suits their needs best. Additionally, patients with Addison's Disease often require regular doctor visits and diagnostic tests to monitor their hormone levels and overall health. These appointments and tests add to the overall cost of managing the condition. Furthermore, patients may need emergency medical care in case of adrenal crises, which can incur substantial healthcare expenses.

Key Market Trends

Research and Development Efforts

Research and development (R&D) efforts have become a significant driving force behind the growth of the global Addison's Disease market. This rare endocrine disorder, characterized by inadequate production of cortisol and aldosterone, affects approximately 100 to 140 individuals per million in developed countries, with a higher prevalence among women aged 30 to 50.

A key focus of R&D in Addison's Disease is the exploration of its genetic underpinnings. Researchers are diligently working to uncover the genetic factors contributing to the development of this condition. Understanding the genetic basis of Addison's Disease not only enhances comprehension of the disorder but also opens doors to more precise and personalized treatment strategies. Identifying specific genetic mutations or predispositions can lead to tailored therapeutic approaches, potentially improving outcomes for affected individuals.

In addition to genetic research, R&D efforts are concentrated on developing novel treatment modalities that go beyond traditional hormone replacement therapy. While hormone replacement remains essential, innovative therapies are being investigated to address the root causes of adrenal insufficiency. Gene therapy, for example, holds promise in correcting genetic defects responsible for Addison's Disease, potentially providing a long-term solution that reduces or eliminates the need for hormone replacement.

Key Market Players

• Teva Pharmaceuticals
• Ralington Pharma
• Aspen Pharma
• Pfizer Inc
• Merck KGA
• Anant Pharmaceuticals
• Symbiotech
• Curia
• AuroPharma
• Parchem Fine & Specialty Chemicals

Report Scope:

In this report, the Global Addison's Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Addison's Disease Market, By Type:

• Primary Adrenal Insufficiency
• Secondary Adrenal Insufficiency
• Tertiary Adrenal Insufficiency

Addison's Disease Market, By Drug Class:

• Oral Corticosteroid
• Corticosteroid Injections
• Sodium Intake

Addison's Disease Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Addison's Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Addison's Disease Market.

Available Customizations:

Global Addison's Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Addison's Disease Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal Insufficiency)
  • 4.2.2. By Drug Class (Oral Corticosteroid, Corticosteroid Injections, Sodium Intake)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Addison's Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Addison's Disease Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Class
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Addison's Disease Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Class
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Addison's Disease Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Class
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Addison's Disease Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Class
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Addison's Disease Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Class
      • 5.3.5.2.3. By Distribution Channel

6. Europe Addison's Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Addison's Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Addison's Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Addison's Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Addison's Disease Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Class
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Addison's Disease Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Class
      • 6.3.5.2.3. By Distribution Channel

7. North America Addison's Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Addison's Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Addison's Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Addison's Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel

8. South America Addison's Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Addison's Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Addison's Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Addison's Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Addison's Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Addison's Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Addison's Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Addison's Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Addison's Disease Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Teva Pharmaceuticals
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Ralington Pharma
• 14.3. Aspen Pharma
• 14.4. Pfizer Inc
• 14.5. Merck KGaA
• 14.6. Anant Pharmaceuticals
• 14.7. Symbiotech
• 14.8. Curia
• 14.9. AuroPharma
• 14.10.Parchem Fine & Specialty Chemicals

15. Strategic Recommendations

16. About Us & Disclaimer